A White Knight for Bausch & Lomb

Bausch & Lomb was slogging forward after a difficult year-the company had been embroiled in a lengthy accounting investigation involving some of its foreign subsidiaries since the end of 2005 and in early 2006 it was compelled to recall its most profitable product-. In mid-May 2007 Bausch & Lomb was wrestling with a 3% decrease in annual sales, 344 product liability lawsuits, and an overhanging intellectual property case that could affect its fastest growing contact lens line, when up galloped white knight private equity firm Warburg Pincus, with a $4.5 billion offer to take the ophthalmic company private.

Bausch & Lomb Inc. was slogging forward after a difficult year—the company had been embroiled in a lengthy accounting investigation involving some of its foreign subsidiaries since the end of 2005 and in early 2006 it was compelled to recall its most profitable product—contact lens solution ReNu with MoistureLoc. In mid-may 2007 Bausch & Lomb was wrestling with a 3% decrease in annual sales, 344 product liability lawsuits, and an overhanging intellectual property case that could affect its fastest growing contact lens line, PureVision, when up galloped white knight Warburg Pincus LLC, with a $4.5 billion offer to take the ophthalmic company private (including the assumption of $830 million in debt.) [See Deal] The offer was 30 times projected 2007 cash flow, according to Standard & Poor’s, and 26 times projected 2007 earnings per share.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo